Development of a Streptococcus gordonii vaccine strain expressing Schistosoma japonicum Sj-F1 and evaluation of using this strain for intranasal immunization in mice

Parasitology Research

Volumn 112, Issue 4, 2013, Pages 1701-1708

  Wang, Linqian ^a   Liu, Wei ^b   Yang, Ming ^b   Peng, Dan ^b   Chen, Liyu ^b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b Central South University   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; M6 SJ F1 FUSION PROTEIN; SCHISTOSOMA VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL STRAIN; CERCARIA; CONTROLLED STUDY; DNA LIBRARY; DRUG EFFECT; FEMALE; GENE; GENE EXPRESSION REGULATION; IMMUNIZATION; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOREACTIVITY; INFECTION PREVENTION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SCHISTOSOMIASIS JAPONICA; SJ F1 GENE; STREPTOCOCCUS GORDONII;

ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, HELMINTH; ANTIGENS, BACTERIAL; ANTIGENS, HELMINTH; BACTERIAL OUTER MEMBRANE PROTEINS; CARRIER PROTEINS; CELL SURFACE DISPLAY TECHNIQUES; DISEASE MODELS, ANIMAL; DRUG CARRIERS; FEMALE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MICE; PARASITE LOAD; RECOMBINANT FUSION PROTEINS; SALIVA; SCHISTOSOMA JAPONICUM; SCHISTOSOMIASIS JAPONICA; STREPTOCOCCUS GORDONII; VACCINES, ATTENUATED; VACCINES, SYNTHETIC;

BACTERIA (MICROORGANISMS); MUS; SCHISTOSOMA JAPONICUM; STREPTOCOCCUS GORDONII; STREPTOCOCCUS PYOGENES;

EID: 84876408364     PISSN: 09320113     EISSN: 14321955     Source Type: Journal    
DOI: 10.1007/s00436-013-3327-1     Document Type: Article

References (23)

1. Caldas IR, Correa-Oliveira R, Colosimo E, Carvalho OS, Massara CL, Colley DG, Gazzinelli G (2000) Susceptibility and resistance to Schistosoma mansoni reinfection: parallel cellular and isotypic immunologic assessment. Am J Trop Med Hyg 62:57-64
2. Ciabattini A, Giomarelli B, Parigi R, Chiavolini D, Pettini E, Aricò B, Giuliani MM, Santini L, Medaglini D, Pozzi G (2008) Intranasal immunization of mice with recombinant Streptococcus gordonii expressing NadA of Neisseria meningitidis induces systemic bactericidal antibodies and local IgA. Vaccine 26:4244-4250
3. + T cells in the genital and intestinal tracts. Vaccine 28:1226-1233
4. Giomarelli B, Maggi T, Younson J, Kelly C, Pozzi G (2004) Expression of a functional single-chain Fv antibody on the surface of Streptococcus gordonii. Mol Biotechnol 28:105-112
5. Gray DJ, Ross AG, Li YS, McManus DP (2011) Diagnosis and management of schistosomiasis. BMJ 342:d2651
6. Gryseels B, Polman K, Clerinx J, Kestens L (2006) Human schistosomiasis. Lancet 368:1106-1118
7. Kallestrup P, Zinyama R, Gomo E, Butterworth AE, van Dam GJ, Gerstoft J, Erikstrup C, Ullum H (2006) Schistosomiasis and HIV in rural Zimbabwe: efficacy of treatment of schistosomiasis in individuals with HIV coinfection. Clin Infect Dis 42:1781-1789
8. King CH, Dangerfield-Cha M (2008) The unacknowledged impact of chronic schistosomiasis. Chronic Illn 4:65-79
9. Kochi SK, Killeen KP, Ryan US (2003) Advances in the development of bacterial vector technology. Expert Rev Vaccines 2:31-43
10. Kohama H, Harakuni T, Kikuchi M, Nara T, Takemura Y, Miyata T, Sato Y, Hirayama K, Arakawa T (2010) Intranasal administration of Schistosoma japonicum paramyosin induced robust long-lasting systemic and local antibody as well as delayed-type hypersensitivity responses, but failed to confer protection in a mouse infection model. Jpn J Infect Dis 63:166-172
11. Lee SF (2003) Oral colonization and immune responses to Streptococcus gordonii: potential use as a vector to induce antibodies against respiratory pathogens. Curr Opin Infect Dis 16:231-235
12. Li L, Hu X, Wu Z, Wang X, Xu J, Lu F, Yu X (2009) Immunogenicity of self-adjuvanticity oral vaccine candidate based on use of Bacillus subtilis spore displaying Schistosoma japonicum 26 KDa GST protein. Parasitol Res 105:1643-1651
13. Li R, Lim A, Alonso S (2011) Attenuated Bordetella pertussis BPZE1 as a live vehicle for heterologous vaccine antigens delivery through the nasal route. Bioen Bugs 26:315-319
14. Mallaley PP, Halperin SA, Morris A, MacMillan A, Lee SF (2006) Expression of a pertussis toxin S1 fragment by inducible promoters in oral Streptococcus and the induction of immune responses during oral colonization in mice. Can J Microbiol 52:436-444
15. Mayer ML, Phillips CM, Stadnyk AW, Halperin SA, Lee SF (2009a) Synergistic BM-DC activation and immune induction by the oral vaccine vector Streptococcus gordonii and exogenous tumor necrosis factor. Mol Immunol 46:1883-1891
16. Mayer ML, Phillips CM, Townsend RA, Halperin SA, Lee SF (2009b) Differential activation of dendritic cells by Toll-like receptor agonists isolated from the Gram-positive vaccine vector Streptococcus gordonii. Scand J Immunol 69:351-356
17. McManus DP, Loukas A (2008) Current status of vaccines for schistosomiasis. Clin Microbiol Rev 21:225-242
18. Medaglini D, Ciabattini A, Spinosa MR, Maggi T, Marcotte H, Oggioni MR, Pozzi G (2001) Immunization with recombinant Streptococcus gordonii expressing tetanus fragment C confers protection from lethal challenge in mice. Vaccine 19:1931-1939
19. Oggioni MR, Pozzi G (1996) A host-vector system for heterologous gene expression in Streptococcus gordonii. Gene 169:85-90
20. Pozzi G, Musmanno RA, Lievens PM, Oggioni MR, Plevani P, Manganelli R (1990) Method and parameters for genetic transformation of Streptococcus sanguis Challis. Res Microbiol 141:659-670
21. Robert-Guroff M (2007) Replicating and non-replicating viral vectors for vaccine development. Curr Opin Biotechnol 18:546-556
22. Siddiqui AA, Siddiqui BA, Ganley-Leal L (2011) Schistosomiasis vaccines. Hum Vaccin 7:1192-1197
23. Steinmann P, Keiser J, Bos R, Tanner M, Utzinger J (2006) Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infect Dis 6:411-425